The DOI matches its Crossref record; 320 of the 320 references it cites were found in a registry or an index.
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
Open accessAbstract
Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor positive (ER+) breast cancer making up approximately 75% of all breast cancers diagnosed. Given the dependence on active ER signaling in these tumors, the predominant treatment strategy has been to inhibit various aspects of this pathway including directly antagonizing ER with the use of selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs). Interestingly, the dependence on ER for breast cancer growth is often retained even after progression through several lines of antiestrogen therapy, making ER a bonafide biomarker for this cancer subtype and driving the continued research and development of novel ER-targeted therapeutics to treat this patient population. This, combined with the continuous discovery of mechanisms underlying endocrine resistance, is resulting in a continually evolving treatment landscape for ER+ breast cancer. This review discusses various ER antagonists investigated for the treatment of breast cancer, outlining their pharmacological and tissue-specific mechanisms of action as well as their specified use within the ER+ breast cancer setting. In addition, mechanisms of resistance to SERMs and SERDs, the use of ER antagonists in combination therapy strategies, and the ongoing development of novel drugs are also reviewed in the context of the changing clinical landscape of ER+ breast cancer. Lastly, the role of SERMs and SERDs in non-breast cancer indications is also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
Two pathogenetic types of endometrial carcinoma
Bokhman, J. V. (1983) · Gynecologic Oncology · doi:10.1016/0090-8258(83)90111-7 · Cited by 2,494
Breast Density and Parenchymal Patterns as Markers of Breast Cancer Risk: A Meta-analysis
McCormack, V. A., & dos Santos Silva, I. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0034 · Cited by 2,143
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Estrogen Carcinogenesis in Breast Cancer
Yager, J. D., & Davidson, N. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050776 · Cited by 1,862
Estrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Genome-wide analysis of estrogen receptor binding sites
Carroll, J. S., Meyer, C. A., Song, J., Li, W., Geistlinger, T. R., Eeckhoute, J., Brodsky, A. S., Keeton, E. K., Fertuck, K. C., Hall, G. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1901 · Cited by 1,377
Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A., Bevers, T. B., Kavanah, M. T., Atkins, J. N., Margolese, R. G., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji372 · Cited by 1,339
Fisher, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., Cronin, W. M., & Contributors, O. N. (1994) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/86.7.527 · Cited by 1,268
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,220
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146
(1991) · PubMed · Cited by 1,101
Human Estrogen Receptor β-Gene Structure, Chromosomal Localization, and Expression Pattern1
Enmark, E., Pelto-Huikko, M., Grandien, K., Lagercrantz, S., Lagercrantz, J., Fried, G., Nordenskjöld, M., & Gustafsson, J.-A. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4470 · Cited by 1,074
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M. A., & Wenger, N. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062462 · Cited by 1,048
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968
Early Breast Cancer Trialists’ Collaborative Group, & Peto, R. (1993) · Recent Results in Cancer Research · doi:10.1007/978-3-642-84745-5_21 · Cited by 958
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast Cancer
Early Breast Cancer Trialists' Collaborative Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198812293192601 · Cited by 933
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Dowsett, M., Cuzick, J., Ingle, J., Coates, A., Forbes, J., Bliss, J., Buyse, M., Baum, M., Buzdar, A., Colleoni, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1274 · Cited by 813
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 786
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09962-2 · Cited by 747
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3746 · Cited by 732
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M., & Schiff, R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.117 · Cited by 704
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474
Cole, M. P., Jones, C. T. A., & Todd, I. D. H. (1971) · British Journal of Cancer · doi:10.1038/bjc.1971.33 · Cited by 701
Martino, S., Cauley, J. A., Barrett-Connor, E., Powles, T. J., Mershon, J., Disch, D., Secrest, R. J., Cummings, S. R., & For the CORE Investigators (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh319 · Cited by 684
Cauley, J. A., Norton, L., Lippman, M. E., Eckert, S., Krueger, K. A., Purdie, D. W., Farrerons, J., Karasik, A., Mellstrom, D., Ng, K. W., et al. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1006478317173 · Cited by 678
Howell, A., Robertson, J. F. R., Quaresma Albano, J., Aschermannova, A., Mauriac, L., Kleeberg, U. R., Vergote, I., Erikstein, B., Webster, A., & Morris, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.057 · Cited by 671
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.
Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.-M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2920 · Cited by 660
Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., Bevers, T. B., Fehrenbacher, L., Pajon, E. R., Wade, J. L., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0076 · Cited by 646
Osborne, C. K., Pippen, J., Jones, S. E., Parker, L. M., Ellis, M., Come, S., Gertler, S. Z., May, J. T., Burton, G., Dimery, I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.058 · Cited by 642
Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636
Rugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L., Fowble, B., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 633
Li, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 626
Robertson, J. F. R., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., Shparyk, Y., Cardona-Huerta, S., Cheung, K.-L., Philco-Salas, M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32389-3 · Cited by 582
Miller, T. W., Hennessy, B. T., González-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., García-Echeverría, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 551
Cuzick, J., Forbes, J. F., Sestak, I., Cawthorn, S., Hamed, H., Holli, K., & Howell, A. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk049 · Cited by 534
NCCN Guidelines Insights: Breast Cancer, Version 1.2017
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0044 · Cited by 529
Saal, L. H., Johansson, P., Holm, K., Gruvberger-Saal, S. K., She, Q.-B., Maurer, M., Koujak, S., Ferrando, A. A., Malmström, P., Memeo, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702507104 · Cited by 520
A MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTIOESTROGENIC ACTIVITY
JORDAN, V. C., COLLINS, M. M., ROWSBY, L., & PRESTWICH, G. (1977) · Journal of Endocrinology · doi:10.1677/joe.0.0750305 · Cited by 506
Gutierrez, M. C., Detre, S., Johnston, S., Mohsin, S. K., Shou, J., Allred, D. C., Schiff, R., Osborne, C. K., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.172 · Cited by 489
Arpino, G., Weiss, H., Lee, A. V., Schiff, R., De Placido, S., Osborne, C. K., & Elledge, R. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji249 · Cited by 484
Cuzick, J., Sestak, I., Cawthorn, S., Hamed, H., Holli, K., Howell, A., & Forbes, J. F. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71171-4 · Cited by 464
Johnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000025406.31193.e8 · Cited by 456
Dowsett, M., Allred, C., Knox, J., Quinn, E., Salter, J., Wale, C., Cuzick, J., Houghton, J., Williams, N., Mallon, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9437 · Cited by 450
A NEW DERIVATIVE OF TRIPHENYLETHYLENE: EFFECT ON IMPLANTATION AND MODE OF ACTION IN RATS
HARPER, M. J. K., & WALPOLE, A. L. (1967) · Reproduction · doi:10.1530/jrf.0.0130101 · Cited by 445
Sieh, W., Köbel, M., Longacre, T. A., Bowtell, D. D., deFazio, A., Goodman, M. T., Høgdall, E., Deen, S., Wentzensen, N., Moysich, K. B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70253-5 · Cited by 433
Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., & Davidson, N. E. (2001) · PubMed · Cited by 430
Powles, T. J., Ashley, S., Tidy, A., Smith, I. E., & Dowsett, M. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk050 · Cited by 430
Wijayaratne, A. L., & McDonnell, D. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101097200 · Cited by 427
Klijn, J. G. M., Blamey, R. W., Boccardo, F., Tominaga, T., Duchateau, L., & Sylvester, R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.343 · Cited by 425
Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.
Gottardis, M. M., Robinson, S. P., SATYASWAROOP, P. G., & Jordan, V. C. (1988) · PubMed · Cited by 422
Fawell, S. E., White, R., Hoare, S., Sydenham, M., Page, M., & Parker, M. G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6883 · Cited by 396
Munster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391
Lasofoxifene in Postmenopausal Women with Osteoporosis
Cummings, S. R., Ensrud, K., Delmas, P. D., LaCroix, A. Z., Vukicevic, S., Reid, D. M., Goldstein, S., Sriram, U., Lee, A., Thompson, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0808692 · Cited by 387
Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels
Ward, H. W. C. (1973) · BMJ · doi:10.1136/bmj.1.5844.13 · Cited by 375
EARLYBREASTCANCERTRIALISTSCOL (1992) · The Lancet · doi:10.1016/0140-6736(92)90139-t · Cited by 375
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., Gralow, J. R., Livingston, R. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201622 · Cited by 371
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
Toy, W., Weir, H., Razavi, P., Lawson, M., Goeppert, A. U., Mazzola, A. M., Smith, A., Wilson, J., Morrow, C., Wong, W. L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1523 · Cited by 368
Gottardis, M. M., & Jordan, V. C. (1987) · PubMed · Cited by 352
Precursor lesions of ovarian epithelial malignancy
Feeley, K. M., & Wells, M. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01042.x · Cited by 351
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
Howell, A., DeFriend, D. J., Blamey, R. W., Robertson, J. F., & Walton, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91156-1 · Cited by 349
Structural Insights into the Mode of Action of a Pure Antiestrogen
Pike, A. C. W., Brzozowski, A. M., Walton, J., Hubbard, R. E., Thorsell, A.-G., Li, Y.-L., Gustafsson, J.-Å., & Carlquist, M. (2001) · Structure · doi:10.1016/s0969-2126(01)00568-8 · Cited by 347
Tamoxifen for Prevention of Breast Cancer
Cersosimo, R. J. (2003) · Annals of Pharmacotherapy · doi:10.1177/106002800303700219 · Cited by 343
De Laurentiis, M., Arpino, G., Massarelli, E., Ruggiero, A., Carlomagno, C., Ciardiello, F., Tortora, G., D'Agostino, D., Caputo, F., Cancello, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2569 · Cited by 340
Ingle, J. N., Ahmann, D. L., Green, S. J., Edmonson, J. H., Bisel, H. F., Kvols, L. K., Nichols, W. C., Creagan, E. T., Hahn, R. G., Rubin, J., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198101013040104 · Cited by 336
Oestrogen-responsive human breast cancer in long term tissue culture
LIPPMAN, M. E., & BOLAN, G. (1975) · Nature · doi:10.1038/256592a0 · Cited by 335
Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., Bevers, T. B., Fehrenbacher, L., Pajon, E. R., Wade, J. L., et al. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000238648.23538.42 · Cited by 329
Risk determination and prevention of breast cancer
Howell, A., Anderson, A. S., Clarke, R. B., Duffy, S. W., Evans, D. G., Garcia-Closas, M., Gescher, A. J., Key, T. J., Saxton, J. M., & Harvie, M. N. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0446-2 · Cited by 327
Wakeling, A. E., & Bowler, J. (1987) · Journal of Endocrinology · doi:10.1677/joe.0.112r007 · Cited by 321
Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
Leo, A. D., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt337 · Cited by 321
Robertson, J. F. R., Osborne, C. K., Howell, A., Jones, S. E., Mauriac, L., Ellis, M., Kleeberg, U. R., Come, S. E., Vergote, I., Gertler, S., et al. (2003) · Cancer · doi:10.1002/cncr.11468 · Cited by 315
The biological role of estrogen receptors α and β in cancer
Pearce, S. T., & Jordan, V. C. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.003 · Cited by 311
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L.-M., Copeland, L., Crispens, M. A., DeRosa, M., Dorigo, O., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0122 · Cited by 311
Robertson, J. F. R., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Macpherson, E., Lindemann, J., & Ellis, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1136 · Cited by 310
Spoerke, J. M., Gendreau, S., Walter, K., Qiu, J., Wilson, T. R., Savage, H., Aimi, J., Derynck, M. K., Chen, M., Chan, I. T., et al. (2016) · Nature Communications · doi:10.1038/ncomms11579 · Cited by 309
Lim, Y. C., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0926-7 · Cited by 309
Thangavel, C., Dean, J. L., Ertel, A., Knudsen, K. E., Aldaz, C. M., Witkiewicz, A. K., Clarke, R., & Knudsen, E. S. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0262 · Cited by 302
Influence of Synthetic Oestrogens on Advanced Malignant Disease
Haddow, A., Watkinson, J., Paterson, E., & KOLLER, P. C. (1944) · BMJ · doi:10.1136/bmj.2.4368.393 · Cited by 299
Molecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action
Dutertre, M., & Smith, C. L. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38923-2 · Cited by 299
Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity
Komm, B. S., Kharode, Y. P., Bodine, P. V. N., Harris, H. A., Miller, C. P., & Lyttle, C. R. (2005) · Endocrinology · doi:10.1210/en.2005-0030 · Cited by 298
Coregulators in Nuclear Estrogen Receptor Action: From Concept to Therapeutic Targeting
Hall, J. M. (2005) · Molecular Interventions · doi:10.1124/mi.5.6.7 · Cited by 295
Krop, I. E., Mayer, I. A., Ganju, V., Dickler, M., Johnston, S., Morales, S., Yardley, D. A., Melichar, B., Forero-Torres, A., Lee, S. C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00106-6 · Cited by 295
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.
DeFriend, D. J., Howell, A., Nicholson, R. I., Anderson, E., Dowsett, M., Mansel, R. E., Blamey, R. W., Bundred, N. J., Robertson, J. F. R., & Saunders, C. M. (1994) · PubMed · Cited by 291
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Normanno, N., Di Maio, M., De Maio, E., De Luca, A., de Matteis, A., Giordano, A., Perrone, F., & _, _. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00857 · Cited by 286
Rustin, G. J. S., Nelstrop, A. E., Tuxen, M. K., & Lambert, H. E. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010602 · Cited by 283
Signaling through cyclin D-dependent kinases
Choi, Y. J., & Anders, L. (2014) · Oncogene · doi:10.1038/onc.2013.137 · Cited by 278
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.
Fuqua, S. A. W., Wiltschke, C., ZHANG, Q. X., Borg, Å., Castles, C. G., Friedrichs, W. E., Hopp, T., Hilsenbeck, S. G., Mohsin, S. K., O'Connell, P., et al. (2000) · PubMed · Cited by 278
Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink, J. J., & Jordan, V. C. (1996) · PubMed · Cited by 276
Johnston, S. R., Kilburn, L. S., Ellis, P., Dodwell, D., Cameron, D., Hayward, L., Im, Y.-H., Braybrooke, J. P., Brunt, A. M., Cheung, K.-L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70322-x · Cited by 274
AKHMEDKHANOV, A., ZELENIUCH‐JACQUOTTE, A., & TONIOLO, P. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03811.x · Cited by 269
Bergh, J., Jönsson, P.-E., Lidbrink, E. K., Trudeau, M., Eiermann, W., Brattström, D., Lindemann, J. P. O., Wiklund, F., & Henriksson, R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.1095 · Cited by 263
Phosphorylation of Human Estrogen Receptor α by Protein Kinase A Regulates Dimerization
Chen, D., Pace, P. E., Coombes, R. C., & Ali, S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1002 · Cited by 260
Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2594 · Cited by 258
Arpino, G., Green, S. J., Allred, D. C., Lew, D., Martino, S., Osborne, C. K., & Elledge, R. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0110 · Cited by 255
García-Becerra, R., Santos, N., Díaz, L., & Camacho, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms14010108 · Cited by 253
The Dynamic Structure of the Estrogen Receptor
Kumar, R., Zakharov, M. N., Khan, S. H., Miki, R., Jang, H., Toraldo, G., Singh, R., Bhasin, S., & Jasuja, R. (2011) · Journal of Amino Acids · doi:10.4061/2011/812540 · Cited by 252
Fiorica, J. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.11.008 · Cited by 249
Fan, M., Yan, P. S., Hartman-Frey, C., Chen, L., Paik, H., Oyer, S. L., Salisbury, J. D., Cheng, A. S. L., Li, L., Abbosh, P. H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1666 · Cited by 248
Traub, L., Thill, M., & Nitschmann, S. (2018) · Der Internist · doi:10.1007/s00108-018-0398-1 · Cited by 248
Lai, A., Kahraman, M., Govek, S., Nagasawa, J., Bonnefous, C., Julien, J., Douglas, K., Sensintaffar, J., Lu, N., Lee, K.-J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00054 · Cited by 247
S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation
Yamnik, R. L., Digilova, A., Davis, D. C., Brodt, Z. N., Murphy, C. J., & Holz, M. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807532200 · Cited by 246
Comparative Analyses of Mechanistic Differences Among Antiestrogens1
Wijayaratne, A. L., Nagel, S. C., Paige, L. A., Christensen, D. J., Norris, J. D., Fowlkes, D. M., & McDonnell, D. P. (1999) · Endocrinology · doi:10.1210/endo.140.12.7164 · Cited by 244
ICI 182,780, a new antioestrogen with clinical potential
Wakeling, A. E., & Bowler, J. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90204-v · Cited by 242
Veronesi, U., Maisonneuve, P., Rotmensz, N., Bonanni, B., Boyle, P., Viale, G., Costa, A., Sacchini, V., Travaglini, R., D'Aiuto, G., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk154 · Cited by 242
Antagonism of estrogen action with a new benzothiophene derived antiestrogen
Black, L. J., Jones, C. D., & Falcone, J. F. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90935-9 · Cited by 239
Ellis, M. J., Llombart-Cussac, A., Feltl, D., Dewar, J. A., Jasiówka, M., Hewson, N., Rukazenkov, Y., & Robertson, J. F. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5831 · Cited by 238
Menasce, L. P., White, G. R. M., Harrison, C. J., & Boyle, J. M. (1993) · Genomics · doi:10.1006/geno.1993.1320 · Cited by 235
LERNER, L. J., HOLTHAUS, F. J., & THOMPSON, C. R. (1958) · Endocrinology · doi:10.1210/endo-63-3-295 · Cited by 233
Structural Basis for an Unexpected Mode of SERM-Mediated ER Antagonism
Wu, Y.-L., Yang, X., Ren, Z., McDonnell, D. P., Norris, J. D., Willson, T. M., & Greene, G. L. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.014 · Cited by 232
McInerney, E. M., & Katzenellenbogen, B. S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.39.24172 · Cited by 222
Hatch, K. D., Beecham, J. B., Blessing, J. A., & Creasman, W. T. (1991) · Cancer · doi:10.1002/1097-0142(19910715)68:2<269::aid-cncr2820680209>3.0.co;2-o · Cited by 220
Houston, S. J., Plunkett, T. A., Barnes, D. M., Smith, P., Rubens, R. D., & Miles, D. W. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690196 · Cited by 220
TAMOXIFEN AND CONTRALATERAL BREAST CANCER
Cuzick, J., & Baum, M. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90338-1 · Cited by 216
Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial
Brinton, L. A., Felix, A. S., McMeekin, D. S., Creasman, W. T., Sherman, M. E., Mutch, D., Cohn, D. E., Walker, J. L., Moore, R. G., Downs, L. S., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.02.023 · Cited by 216
Robertson, J. F. R., Nicholson, R. I., Bundred, N. J., Anderson, E., Rayter, Z., Dowsett, M., Fox, J. N., Gee, J. M. W., Webster, A., Wakeling, A. E., et al. (2001) · PubMed · Cited by 216
Novel antioestrogens without partial agonist activity
Wakeling, A. E., & Bowler, J. (1988) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(88)90014-3 · Cited by 214
Novel steroidal pure antiestrogens
Bowler, J., Lilley, T. J., Pittam, J. D., & Wakeling, A. E. (1989) · Steroids · doi:10.1016/0039-128x(89)90076-7 · Cited by 206
McDonnell, D. P., & Wardell, S. E. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.09.007 · Cited by 203
Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated Levels
Rustin, G. J. S., Marples, M., Nelstrop, A. E., Mahmoudi, M., & Meyer, T. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4054 · Cited by 201
Tamoxifen: Catalyst for the change to targeted therapy
Jordan, V. C. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.11.002 · Cited by 199
Targeting the RB-E2F pathway in breast cancer
Johnson, J., Thijssen, B., McDermott, U., Garnett, M., Wessels, L. F. A., & Bernards, R. (2016) · Oncogene · doi:10.1038/onc.2016.32 · Cited by 199
Klinge, C. M., Jernigan, S. C., Mattingly, K. A., Risinger, K. E., & Zhang, J. (2004) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01541 · Cited by 197
Hormonal Pathogenesis of Adenocarcinoma of the Breast
Lacassagne, A. (1936) · The American Journal of Cancer · doi:10.1158/ajc.1936.217 · Cited by 194
Whitney, C. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.09.018 · Cited by 193
Kemp, D. C., Fan, P. W., & Stevens, J. C. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.6.694 · Cited by 193
Thigpen, T., Brady, M. F., Homesley, H. D., Soper, J. T., & Bell, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.364 · Cited by 191
Estrogen receptor beta in breast cancer
Haldosén, L.-A., Zhao, C., & Dahlman-Wright, K. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.005 · Cited by 189
Breast cancer risk-assessment models
Evans, D. G. R., & Howell, A. (2007) · Breast Cancer Research · doi:10.1186/bcr1750 · Cited by 185
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
Waters, E. A., McNeel, T. S., Stevens, W. M., & Freedman, A. N. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2089-2 · Cited by 181
McDonnell, D. P., Wardell, S. E., & Norris, J. D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00760 · Cited by 178
Palkowitz, A. D., Glasebrook, A. L., Thrasher, K. J., Hauser, K. L., Short, L. L., Phillips, D. L., Muehl, B. S., Sato, M., Shetler, P. K., Cullinan, G. J., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970167b · Cited by 177
Veeraraghavan, J., Tan, Y., Cao, X.-X., Kim, J. A., Wang, X., Chamness, G. C., Maiti, S. N., Cooper, L. J. N., Edwards, D. P., Contreras, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms5577 · Cited by 176
Grese, T. A., Cho, S., Finley, D. R., Godfrey, A. G., Jones, C. D., Lugar, C. W., Martin, M. J., Matsumoto, K., Pennington, L. D., Winter, M. A., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm9606352 · Cited by 176
Sansone, P., Ceccarelli, C., Berishaj, M., Chang, Q., Rajasekhar, V. K., Perna, F., Bowman, R. L., Vidone, M., Daly, L., Nnoli, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10442 · Cited by 176
Weir, H. M., Bradbury, R. H., Lawson, M., Rabow, A. A., Buttar, D., Callis, R. J., Curwen, J. O., de Almeida, C., Ballard, P., Hulse, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2357 · Cited by 175
Dowsett, M., Harper-Wynne, C. L., Boeddinghaus, I., Salter, J., Hills, M., Dixon, M., Ebbs, S. R., Gui, G. P., Sacks, N., & Smith, I. E. (2001) · PubMed · Cited by 172
Robertson, J. F. R., Lindemann, J. P. O., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Emerson, L., Dean, A., & Ellis, M. J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2192-4 · Cited by 172
Bostner, J., Ahnström Waltersson, M., Fornander, T., Skoog, L., Nordenskjöld, B., & Stål, O. (2007) · Oncogene · doi:10.1038/sj.onc.1210506 · Cited by 172
Stendahl, M., Kronblad, Å., Rydén, L., Emdin, S., Bengtsson, N. O., & Landberg, G. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601831 · Cited by 169
Métivier, R., Penot, G., Flouriot, G., & Pakdel, F. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.11.0727 · Cited by 168
General Molecular Biology and Architecture of Nuclear Receptors
Pawlak, M., Lefebvre, P., & Staels, B. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436641 · Cited by 167
Wardell, S. E., Marks, J. R., & McDonnell, D. P. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.03.031 · Cited by 166
Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer
Jordan, V. C. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-14-0092 · Cited by 165
Palbociclib: First Global Approval
Dhillon, S. (2015) · Drugs · doi:10.1007/s40265-015-0379-9 · Cited by 165
Pharmacogenomics of Tamoxifen Therapy
Brauch, H. B., Mürdter, T. E., Eichelbaum, M. F., & Schwab, M. G. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.121756 · Cited by 164
Garner, F., Shomali, M., Paquin, D., Lyttle, C. R., & Hattersley, G. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000271 · Cited by 162
Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α
Vesuna, F., Lisok, A., Kimble, B., Domek, J., Kato, Y., van der Groep, P., Artemov, D., Kowalski, J., Carraway, H., van Diest, P., et al. (2012) · Oncogene · doi:10.1038/onc.2011.483 · Cited by 161
De Savi, C., Bradbury, R. H., Rabow, A. A., Norman, R. A., de Almeida, C., Andrews, D. M., Ballard, P., Buttar, D., Callis, R. J., Currie, G. S., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00984 · Cited by 161
Bihani, T., Patel, H. K., Arlt, H., Tao, N., Jiang, H., Brown, J. L., Purandare, D. M., Hattersley, G., & Garner, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2561 · Cited by 161
Self-citationWardell, S. E., Ellis, M. J., Alley, H. M., Eisele, K. J., VanArsdale, T. L., Dann, S. G., Arndt, K. T., Primeau, T. M., Griffin, E., Shao, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0360 · Cited by 160
Marsaud, V., Gougèlet, A., Maillard, S., & Renoir, J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0269 · Cited by 160
A structural biologist's view of the oestrogen receptor
Pike, A. C. W., Brzozowski, A. M., & Hubbard, R. E. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00102-3 · Cited by 158
Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study
Zeleniuch-Jacquotte, A., Akhmedkhanov, A., Kato, I., Koenig, K. L., Shore, R. E., Kim, M. Y., Levitz, M., Mittal, K. R., Raju, U., Banerjee, S., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1704 · Cited by 158
Optimal management of hormone receptor positive metastatic breast cancer in 2016
Reinert, T., & Barrios, C. H. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015608993 · Cited by 158
Girault, I., Lerebours, F., Amarir, S., et al. (2003) · PubMed · Cited by 157
Fox, E. M., Miller, T. W., Balko, J. M., Kuba, M. G., Sanchez, V. M., Smith, R. A., Liu, S., Gonzalez-Angulo, A. M., Mills, G. B., Ye, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1295 · Cited by 154
Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report
Markman, M., Iseminger, K. A., Hatch, K. D., Creasman, W. T., Barnes, W. A., & DuBeshter, B. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0181 · Cited by 151
Correction to: 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J. C. S., Bhattacharyya, G. S., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx036 · Cited by 151
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial
Vogel, V. G. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.1.51 · Cited by 150
Biology and mode of action of pure antioestrogens.
Wakeling, A. E., & Bowler, J. (1988) · PubMed · doi:10.1016/0022-4731(88)90086-6 · Cited by 150
Wardell, S. E., Nelson, E. R., Chao, C., & McDonnell, D. P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3771 · Cited by 149
Willson, T. M., Henke, B. R., Momtahen, T. M., Charifson, P. S., Batchelor, K. W., Lubahn, D. B., Moore, L. B., Oliver, B. B., Sauls, H. R., Triantafillou, J. A., et al. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00037a002 · Cited by 146
Tamoxifen Resistance: Emerging Molecular Targets
Rondón‐Lagos, M., Villegas, V. E., Rangel, N., Sánchez, M. C., & Zaphiropoulos, P. G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081357 · Cited by 146
Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
Sideras, K., Ingle, J. N., Ames, M. M., Loprinzi, C. L., Mrazek, D. P., Black, J. L., Weinshilboum, R. M., Hawse, J. R., Spelsberg, T. C., & Goetz, M. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8931 · Cited by 145
A new triphenylethylene compound, Fc-1157a: I. Hormonal effects
Kallio, S., Kangas, L., Blanco, G. A. C., Johansson, R. T., Karjalainen, A., Peril�, M., Pippo, I., Sundquist, H., S�dervall, M., & Toivola, R. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00306736 · Cited by 145
CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
Gao, T., Han, Y. K., Yu, L., Ao, S., Li, Z., & Ji, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091771 · Cited by 143
Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen
Shoman, N. M., Klassen, S., McFadden, A., Bickis, M., Torlakovic, E., & Chibbar, R. (2004) · Modern Pathology · doi:10.1038/modpathol.3800296 · Cited by 142
Derailed Estrogen Signaling and Breast Cancer: An Authentic Couple
Manavathi, B., Dey, O., Gajulapalli, V. N. R., Bhatia, R. S., Bugide, S., & Kumar, R. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1057 · Cited by 142
Liu, X.-F., & Bagchi, M. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311932200 · Cited by 139
Implication of proteasome in estrogen receptor degradation
Khissiin, A. E., & Leclercq, G. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00343-9 · Cited by 139
The changing role of ER in endocrine resistance
Nardone, A., Angelis, C. D., Trivedi, M. V., Osborne, C. K., & Schiff, R. (2015) · The Breast · doi:10.1016/j.breast.2015.07.015 · Cited by 138
Design, Synthesis, and Preclinical Characterization of Novel, Highly Selective Indole Estrogens
Miller, C. P., Collini, M. D., Tran, B. D., Harris, H. A., Kharode, Y. P., Marzolf, J. T., Moran, R. A., Henderson, R. A., Bender, R. H. W., Unwalla, R. J., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010086m · Cited by 137
Rosati, R. L., Jardine, P. D. S., Cameron, K. O., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980048b · Cited by 135
Jirström, K., Stendahl, M., Rydén, L., Kronblad, Å., Bendahl, P.-O., Stål, O., Landberg, G., & Groups., T. S. S. A. S. S. B. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0746 · Cited by 134
Walker, A. J., Wedam, S. B., Amiri‐Kordestani, L., Bloomquist, E. W., Tang, S., Sridhara, R., Chen, W., Palmby, T. R., Zirkelbach, J. F., Fu, W., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0493 · Cited by 133
Connor, C. E., Norris, J. D., Broadwater, G., Willson, T. M., Gottardis, M. M., Dewhirst, M. W., & McDonnell, D. P. (2001) · PubMed · Cited by 131
Cited by
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
The lingering mysteries of metastatic recurrence in breast cancer
Riggio, A. I., Varley, K. E., & Welm, A. L. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01161-4 · Cited by 616
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer
Clusan, L., Ferrière, F., Flouriot, G., & Pakdel, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076834 · Cited by 382
Metadata
- Authors
- Patel, H. K., & Bihani, T.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 186
- Pages
- 1-24
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2777085303
- Cited by
- 499
- References
- 320
- FWCI
- 13.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.